Mitazalimab

Mitazalimab is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Alligator Bioscience AB, in pancreatic ductal adenocarcinoma. An antibody-drug conjugate, as described in the registry record: an antibody against a tumour surface protein carries a cytotoxic payload into the cell. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.